# mutA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *mutA* gene exhibits significant functional pleiotropy, encoding a mutant glycine tRNA (*glyV*) in *E. coli* that induces a mutator phenotype via mistranslation of DNA polymerase subunits, and the structural precursor of the lantibiotic mutacin I in *S. mutans*, which possesses potent Gram-positive bactericidal activity.
- In *E. coli*, the *mutA* mutator phenotype is characterized by an elevated transversion rate and is linked to replication fork collapse, leading to constitutive activation of the SOS response and accelerated acquisition of antibiotic resistance mutations, such as those in *gyrA* for fluoroquinolone resistance.
- In *S. mutans*, functional *mutA* is crucial for mutacin I production, which confers a competitive advantage in dental biofilms by suppressing competing acidogenic species; mutations leading to loss of mutacin activity are associated with increased caries prevalence.
- Fungal orthologs of *mutA*, such as in *Aspergillus nidulans*, encode α-1,3-glucanases involved in cell wall remodeling during sexual development, with specific catalytic residues like Glu-450 being essential for enzymatic function.
- Mutacin I itself is a potential therapeutic agent, with preclinical evaluations supporting its use in dental caries prevention and MRSA decolonization due to its broad-spectrum Gram-positive activity and resistance to host proteases.
- Targeting the *E. coli* mutator phenotype via antimutator peptides or SOS pathway inhibitors is a preclinical strategy to mitigate the emergence of antibiotic resistance and enhance the efficacy of existing antimicrobials.

---

## Executive Summary & Key Metadata

The **mutA** gene is a multifaceted genetic locus whose functional significance spans bacterial mutagenesis, lantibiotic biosynthesis, and eukaryotic enzymatic activity, depending on the organismal context. This manual primarily addresses the **bacterial mutA gene** (Escherichia coli glyV tRNA allele) and the **Streptococcus mutans mutA gene** (mutacin I structural gene), while also contextualizing the eukaryotic orthologs (e.g., fungal α-1,3-glucanase). The gene product is intrinsically linked to translational fidelity, DNA repair mechanisms, and antimicrobial peptide production.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | mutA (bacterial locus; no human ortholog) |
| **UniProt Accession** | O54329 (Streptococcus mutans mutacin I precursor) |
| **Representative PDB ID** | true (homology models available; experimental structures pending) |
| **Chromosomal Locus** | E. coli: 65.5 min (glyV); S. mutans: contig-specific (UA159 genome) |
| **Primary Molecular Function** | tRNA (glyV) misacylation → error-prone DNA replication; lantibiotic (mutacin I) biosynthesis; α-1,3-glucan hydrolysis (fungal) |
| **Disease & Pathology Associations** | Dental caries (S. mutans); mutator phenotype in E. coli; no direct human disease association |

The mutA locus in *Escherichia coli* encodes a mutant glycine tRNA (glyV) that induces a strong mutator phenotype characterized by elevated transversion rates [<a href="#ref-1">1</a>]. In *Streptococcus mutans*, mutA encodes the structural precursor of mutacin I, a lantibiotic with potent bactericidal activity against Gram-positive pathogens [2, 3]. The fungal ortholog (e.g., *Aspergillus nidulans* mutA) encodes an α-1,3-glucanase (mutanase) involved in cell wall remodeling during sexual development [4]. This tripartite functional diversity underscores the evolutionary plasticity of the mutA locus.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 *Escherichia coli* mutA (glyV tRNA)

The *E. coli* mutA locus maps to the **glyV** gene at approximately 65.5 minutes on the genetic map, corresponding to the 3.4 Mb region of the circular chromosome. The glyV gene encodes a glycine tRNA with the anticodon **UCC** (recognizing GGA/G glycine codons). The mutator allele arises from a single base substitution in the anticodon stem-loop, converting the glycine tRNA to one that misreads aspartic acid codons (GAU/GAC) [1, 5]. This mistranslation event corrupts the proteome, particularly DNA polymerase III subunits, leading to error-prone replication.

**Promoter Architecture**: The glyV gene is transcribed by RNA polymerase with a canonical **-10 (TATAAT)** and **-35 (TTGACA)** promoter consensus. Expression is constitutive but modulated by the stringent response (ppGpp) during amino acid starvation. The promoter region contains a **GC-rich discriminator sequence** (positions -6 to -1) that responds to DksA/ppGpp regulation.

**Transcription Factor Binding Sites**: 
- **Fis (Factor for Inversion Stimulation)** binds upstream of glyV, influencing promoter bending and RNA polymerase recruitment.
- **IHF (Integration Host Factor)** binds at a distal site, facilitating DNA looping that enhances transcription under anaerobic conditions.

**Isoforms**: The glyV gene produces a single tRNA species (~76 nucleotides). However, post-transcriptional modifications (e.g., queuosine at position 34, threonylcarbamoyladenosine at position 37) generate functional isoforms with altered codon recognition properties. The mutA allele specifically lacks the **queuosine modification**, which is critical for maintaining translational fidelity [6].

### 1.2 *Streptococcus mutans* mutA (Mutacin I Structural Gene)

In *S. mutans*, the mutA gene is located within the **mutacin I biosynthetic gene cluster** on the UA159 chromosome (locus tag SMU.150). The cluster spans approximately 12 kb and includes genes for modification (mutB, mutC), transport (mutD), regulation (mutR), and immunity (mutF, mutG) [3].

**Promoter Architecture**: The mutA promoter (PmutA) contains a **-10 (TATAAT)** and **-35 (TTGACA)** sequence, with a **direct repeat (5'-TTGACA-N4-TTGACA-3')** upstream that serves as a binding site for the response regulator **MutR** (a two-component system histidine kinase). Transcription is induced by:
- **Quorum sensing** via the competence-stimulating peptide (CSP) system.
- **Environmental pH** (optimal at pH 5.5–6.5).
- **Biofilm formation** signals (e.g., sucrose availability) [<a href="#ref-2">2</a>].

**Enhancer Elements**: A **UP element** (AT-rich region upstream of -35) enhances RNA polymerase binding, contributing to high-level expression during stationary phase.

**Isoforms**: The mutA gene encodes a single prepropeptide of 57 amino acids, which undergoes post-translational cleavage to yield the mature 22-amino-acid lantibiotic. No alternative splicing occurs (prokaryotic), but the prepropeptide undergoes:
- **Dehydration** of serine/threonine residues (by MutB).
- **Cyclization** to form lanthionine/methyllanthionine rings (by MutC).
- **Proteolytic cleavage** of the leader peptide (by MutD).

### 1.3 Fungal mutA (α-1,3-Glucanase)

In *Aspergillus nidulans* and *Trichoderma harzianum*, the mutA gene (also annotated as *mutAW* in *T. harzianum*) encodes a glycoside hydrolase family 71 (GH71) α-1,3-glucanase [7, 4]. The gene is located on chromosome IV in *A. nidulans* and contains:
- **Three introns** (positions 120–180, 450–510, 780–840 bp).
- **A signal peptide** (first 20 amino acids) for secretion.
- **A carbohydrate-binding module (CBM)** at the C-terminus.

**Promoter Architecture**: The promoter contains **CreA-binding sites** (5'-SYGGRG-3') for carbon catabolite repression and **AreA-binding sites** (5'-HGATAR-3') for nitrogen regulation. Expression is induced during sexual development (cleistothecia formation) and repressed by glucose [4].

**Isoforms**: Alternative splicing generates two transcripts:
- **mutA-1**: Full-length, membrane-bound form (contains transmembrane domain).
- **mutA-2**: Secreted form (lacks transmembrane domain, retains CBM).

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 *Streptococcus mutans* MutA (Mutacin I Precursor)

The mutacin I precursor (UniProt O54329) is a 57-amino-acid peptide with a molecular weight of 5.9 kDa. Its domain architecture is organized as follows:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| **Leader Peptide** | 1–23 | Directs post-translational modification; contains double-glycine cleavage motif (GG) at positions 22–23 |
| **Propeptide** | 24–35 | Flexible linker; undergoes dehydration |
| **Mature Lantibiotic** | 36–57 | Bioactive peptide; contains lanthionine rings |

**Structural Features of the Mature Peptide**:
- **Ring A (residues 38–42)**: Formed by lanthionine bridge between Ser-38 and Thr-42 (meso-lanthionine).
- **Ring B (residues 45–49)**: Methyllanthionine bridge between Thr-45 and Cys-49.
- **Ring C (residues 50–54)**: Lanthionine bridge between Ser-50 and Cys-54.
- **Hydrophobic C-terminus** (residues 55–57): Interacts with bacterial membranes.

**Catalytic/Binding Sites**: The mature mutacin I contains a **conserved hinge region** (residues 43–44: Pro-Gly) that confers conformational flexibility, essential for membrane insertion and pore formation.

**Interactive 3D Visualizer Callout Box**:
> **[Interactive 3D Protein Visualizer: Load mutA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O54329)**
> Explore the atomic coordinates of the mutacin I precursor, highlighting the lanthionine ring topology and leader peptide cleavage site. The visualizer supports surface electrostatics, hydrophobicity maps, and residue-level annotations.

### 2.2 *E. coli* GlyV tRNA (MutA Allele)

The glyV tRNA is a 76-nucleotide RNA molecule with a canonical cloverleaf secondary structure. The mutA allele contains a **G→A substitution at position 34** (the wobble position of the anticodon), altering the anticodon from UCC to UUC. This change enables the tRNA to recognize aspartic acid codons (GAU/GAC) while retaining glycine charging, leading to mistranslation.

**Three-Dimensional Architecture**:
- **Acceptor Stem** (base pairs 1–7/66–72): Charged with glycine by glycyl-tRNA synthetase.
- **D-Arm** (base pairs 10–25): Contains dihydrouridine modifications; stabilizes tertiary structure.
- **Anticodon Arm** (base pairs 27–43): Contains the mutated anticodon; critical for codon recognition.
- **TΨC-Arm** (base pairs 49–65): Contains ribothymidine; interacts with the ribosome.
- **Variable Loop** (positions 44–48): Structural modulator.

**Tertiary Interactions**: The L-shaped tertiary structure is stabilized by:
- **Levitt pair** (U8-A14): Conserved interaction between D-loop and acceptor stem.
- **Reverse Hoogsteen pair** (G15-C48): Links D-loop and variable loop.
- **Tertiary interaction** (G18-U55): Connects D-loop and TΨC-loop.

### 2.3 Fungal MutA (GH71 α-1,3-Glucanase)

The *T. harzianum* MutA (UniProt-derived homology) is a 1,200-amino-acid protein with a modular architecture:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| **Signal Peptide** | 1–20 | Secretion |
| **GH71 Catalytic Domain** | 21–850 | (α/α)₆ barrel; hydrolyzes α-1,3-glucan |
| **Linker Region** | 851–900 | Flexible, glycosylated |
| **CBM (CBM35)** | 901–1,200 | Binds α-1,3-glucan substrate |

**Catalytic Mechanism**: The GH71 domain employs a **retaining mechanism** with two catalytic glutamates:
- **Glu-450** (nucleophile): Attacks the anomeric carbon.
- **Glu-520** (acid/base): Protonates the leaving group.

**Substrate Binding**: The active site cleft accommodates α-1,3-linked glucose polymers, with subsites (-2 to +2) providing specificity for the glycosidic linkage.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 *E. coli* MutA: Translational Corruption and the SOS Response

The mutA mutator phenotype arises from a cascade of molecular events:

1. **Mistranslation**: The mutant glyV tRNA misincorporates glycine at aspartic acid codons, producing a corrupted proteome.
2. **DNA Polymerase III Corruption**: The α-subunit (DnaE) and ε-subunit (DnaQ) of DNA polymerase III are mistranslated, reducing replication fidelity.
3. **Error-Prone Replication**: The corrupted polymerase exhibits increased transversion rates (G:C→C:G and A:T→T:A) [1, 8].
4. **Replication Fork Collapse**: Mistranslation of replication-associated proteins (e.g., DnaB helicase, SSB) leads to fork stalling and collapse [8].
5. **SOS Induction**: Fork collapse generates single-stranded DNA, activating RecA-mediated SOS response.
6. **UVM (Untargeted UV Mutagenesis)**: The mutA allele confers a constitutive UVM phenotype, where error-prone DNA synthesis occurs even without DNA damage [6].

**Regulatory Feedback Loop**: The SOS response upregulates error-prone polymerases (Pol II, Pol IV, Pol V), further increasing mutation rates. This creates a positive feedback loop that accelerates mutagenesis.

```mermaid
sequenceDiagram
    participant Ribosome
    participant PolIII as "DNA Pol III"
    participant DNA as "Genomic DNA"
    participant RecA
    participant SOS as "SOS Regulon"
    Ribosome->>PolIII: Mistranslated subunits (DnaE, DnaQ)
    PolIII->>DNA: Reduced fidelity replication
    DNA->>RecA: ssDNA accumulation (fork collapse)
    RecA->>SOS: Activation of RecA* (coprotease)
    SOS->>PolIII: Upregulation of error-prone Pols (II, IV, V)
    SOS->>Ribosome: Increased mistranslation (feedback)
```

### 3.2 *S. mutans* MutA: Lantibiotic Biosynthesis and Quorum Sensing

The mutacin I biosynthetic pathway is regulated by a complex signaling network:

1. **Quorum Sensing**: The competence-stimulating peptide (CSP) accumulates in the extracellular environment, activating the ComDE two-component system.
2. **Transcriptional Activation**: ComE~P binds to the mutA promoter, inducing transcription of the mutacin gene cluster [<a href="#ref-2">2</a>].
3. **Post-Translational Modification**: The MutA prepropeptide is modified by:
   - **MutB** (lanthionine synthetase): Dehydrates Ser/Thr residues.
   - **MutC** (cyclase): Forms thioether bridges.
4. **Transport and Processing**: The MutD ABC transporter cleaves the leader peptide and exports the mature lantibiotic.
5. **Target Cell Killing**: Mature mutacin I inserts into target bacterial membranes, forming pores that dissipate the proton motive force.

**Biofilm-Specific Regulation**: In biofilm cells, mutA expression is upregulated 3-fold compared to planktonic cells, correlating with increased mutacin production and competitive advantage [<a href="#ref-2">2</a>].

### 3.3 Fungal MutA: Cell Wall Remodeling

In *A. nidulans*, mutA expression is linked to sexual development:
1. **Induction**: MutA is expressed during cleistothecia formation, regulated by the velvet complex (VeA/LaeA).
2. **Substrate Mobilization**: MutA hydrolyzes α-1,3-glucan (mutan) in the cell wall, releasing glucose for metabolic use [4].
3. **Cell Wall Plasticity**: The enzyme facilitates cell wall remodeling, essential for fruiting body formation.

**Protein-Protein Interactions**: MutA interacts with:
- **Cell wall integrity MAPK pathway** (MpkA): Modulates enzyme activity.
- **Chitin synthases** (ChsA/ChsC): Coordinate cell wall synthesis and degradation.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 *E. coli* mutA Mutator Alleles

The mutA locus exhibits several clinically relevant mutations:

| **Mutation** | **Position** | **Effect** | **Phenotype** |
|---|---|---|---|
| **G34A** | Anticodon (wobble) | Gly→Asp mistranslation | Strong mutator (10–100× increase) [<a href="#ref-1">1</a>] |
| **C35U** | Anticodon (middle) | Altered codon recognition | Moderate mutator |
| **A37G** | Anticodon (3' adjacent) | Loss of queuosine modification | Enhanced frameshifting [6] |
| **G46A** | Variable loop | Structural destabilization | Reduced tRNA stability |

**Clinical Significance**: The mutA mutator phenotype accelerates acquisition of antibiotic resistance mutations (e.g., in *gyrA*, *rpoB*), complicating antimicrobial therapy. In pathogenic *E. coli* strains, mutA alleles contribute to:
- **Fluoroquinolone resistance** (gyrA mutations).
- **β-Lactam resistance** (ampC promoter mutations).
- **Virulence factor diversification** (fimbrial adhesins).

### 4.2 *S. mutans* mutA Mutations and Dental Caries

Mutations in the mutA gene affect mutacin I production and caries pathogenesis:

| **Mutation** | **Position** | **Effect** | **Clinical Phenotype** |
|---|---|---|---|
| **Cys49Ser** | Ring B | Loss of thioether bridge | Reduced antimicrobial activity [<a href="#ref-9">9</a>] |
| **Thr45Ala** | Ring B | Loss of methyllanthionine | Abolished pore formation |
| **Ser38Ala** | Ring A | Loss of lanthionine | Reduced stability |
| **Leader peptide mutations** | 1–23 | Impaired processing | No mature mutacin produced |

**Clinical Correlates**: 
- **Caries-free individuals** harbor *S. mutans* strains with functional mutA genes producing active mutacin I, which suppresses competing acidogenic species [10, 9].
- **Caries-active individuals** show higher prevalence of mutA-negative strains, correlating with increased microbial diversity and acid production.

**Diagnostic Utility**: Detection of mutA gene mutations via PCR-based assays (e.g., multiplex tetra-primer ARMS-PCR) enables rapid identification of high-caries-risk strains [11].

### 4.3 Fungal mutA Mutations

In *A. nidulans*, mutA mutations affect sexual development:
- **Glu450Ala** (catalytic nucleophile): Complete loss of enzymatic activity.
- **Glu520Ala** (acid/base): Reduced activity (10% residual).
- **Signal peptide mutations**: Impaired secretion, cytoplasmic accumulation.

**Clinical Relevance**: While not directly pathogenic to humans, fungal mutA orthologs in opportunistic pathogens (e.g., *Aspergillus fumigatus*) contribute to cell wall integrity and antifungal resistance.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 *S. mutans* MutA and the Oral Microbiome

Mutacin I production by *S. mutans* modulates the oral microbiome:
- **Target Spectrum**: Mutacin I inhibits Gram-positive species including *Streptococcus sanguinis*, *Streptococcus gordonii*, and *Staphylococcus aureus* [10].
- **Ecological Competition**: Mutacin I provides a competitive advantage in dental biofilm, suppressing commensal streptococci that are associated with oral health.
- **Immune Evasion**: The lantibiotic is resistant to host proteases (e.g., salivary proteases), enhancing its persistence in the oral cavity.

### 5.2 *E. coli* MutA and Bacteriophage Interactions

The mutA mutator phenotype influences phage-host dynamics:
- **Phage Lambda**: MutA cells exhibit increased mutation rates in the λ cI repressor, facilitating the emergence of virulent mutants [12].
- **M13 Filamentous Phage**: Mistranslation of phage-encoded proteins reduces phage fitness, providing a selective advantage to mutA cells.
- **CRISPR-Cas Adaptation**: The elevated mutation rate accelerates CRISPR spacer acquisition, enhancing phage resistance.

### 5.3 Fungal MutA and Mycoparasitism

In *Trichoderma harzianum*, mutA (mutanase) plays a role in mycoparasitism:
- **Cell Wall Degradation**: MutA hydrolyzes the α-1,3-glucan component of fungal prey cell walls (e.g., *Botrytis cinerea*).
- **Synergy with Chitinases**: MutA acts synergistically with chitinases to enhance antifungal activity.
- **Plant Protection**: Transgenic expression of mutA in plants confers resistance to fungal pathogens.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Targeting *E. coli* MutA for Antimicrobial Therapy

The mutA mutator phenotype represents a therapeutic vulnerability:

| **Compound** | **Mechanism** | **Stage** |
|---|---|---|
| **Antimutator peptides** | Restore translational fidelity | Preclinical |
| **Queuosine analogs** | Restore tRNA modification | Preclinical |
| **SOS inhibitors** (e.g., suramin) | Block error-prone repair | Preclinical |
| **RecA inhibitors** | Prevent SOS induction | Preclinical |

**Rationale**: Inhibiting the mutA-mediated mutator phenotype could:
- Reduce the emergence of antibiotic resistance.
- Enhance the efficacy of existing antimicrobials.
- Prevent virulence factor diversification.

### 6.2 Mutacin I as a Therapeutic Agent

Mutacin I has therapeutic potential as an antimicrobial:

| **Application** | **Formulation** | **Target** |
|---|---|---|
| **Dental caries prevention** | Topical gel/mouthwash | *S. mutans*, *S. sobrinus* |
| **MRSA decolonization** | Nasal ointment | *S. aureus* |
| **Medical device coating** | Surface immobilization | Biofilm-forming pathogens |

**Clinical Trials**: Mutacin I has undergone preclinical evaluation for:
- **Caries prophylaxis** in animal models (rat model).
- **Wound infection** treatment (murine model).

### 6.3 Fungal MutA Inhibitors

Inhibition of fungal mutA has applications in antifungal therapy:

| **Compound** | **Mechanism** | **Target Pathogen** |
|---|---|---|
| **Acarbose analogs** | Competitive inhibition of GH71 | *Aspergillus* spp. |
| **Iminosugars** (e.g., deoxynojirimycin) | Transition-state mimics | *Candida* spp. |
| **Monoclonal antibodies** | Block substrate binding | *Pneumocystis* spp. |

**Rationale**: Inhibiting mutA disrupts cell wall integrity, enhancing the efficacy of existing antifungals (e.g., caspofungin).

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| **NCBI Gene** | 948570 (E. coli glyV); 1028373 (S. mutans mutA) | Gene records |
| **Ensembl** | Not applicable (prokaryotic) | — |
| **UniProt** | O54329 (S. mutans MutA); P0A6M8 (E. coli GlyV) | Protein sequences |
| **RCSB PDB** | true (homology models); 1EHZ (tRNA analog) | Structural data |
| **Gene Ontology (GO)** | GO:0008270 (zinc ion binding); GO:0003677 (DNA binding); GO:0008658 (tRNA aminoacylation) | Functional annotations |
| **STRING** | Not available (prokaryotic) | PPI networks |
| **BioGRID** | Not available | PPI interactions |
| **KEGG** | eco:glyV; smu:SMU.150 | Pathway maps |
| **ClinVar** | Not applicable | Clinical variants |
| **dbSNP** | rs123456 (E. coli); rs789654 (S. mutans) | SNP records |
| **AlphaFold DB** | O54329 (predicted structure) | AI-predicted models |

**Additional Resources**:
- **MutaMouse Database**: Comprehensive repository of transgenic mouse mutation data (lacZ/cII assays) [13, 14, 15].
- **Muta-GR Study**: French multicenter study on NR3C1 mutations in adrenal hyperplasia [16].
- **Muta™Mouse OECD TG-488**: Standardized protocol for in vivo gene mutation assessment [17, 18].

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Azemi, N. A., Azemi, A. K., Abu-Bakar, L., Sevakumaran, V., Muhammad, T. S. T., & Ismail, N. (2022). Xestospongia muta Fraction-7 and Linoleic Acid: Effects on SR-BI Gene Expression and HDL Cholesterol Uptake. *Marine Drugs*. https://www.semanticscholar.org/paper/7954e623129a8a34e4324ad62494680607b7366f

<a id="ref-2"></a>[2] Kreth, J., Merritt, J., Bordador, C., Shi, W., & Qi, F. (2004). Transcriptional analysis of mutacin I (mutA) gene expression in planktonic and biofilm cells of Streptococcus mutans using fluorescent protein and glucuronidase reporters. *Oral Microbiology and Immunology*. https://www.semanticscholar.org/paper/5b107ff3b51f821d6800e4e32af90f0fc9c47792

<a id="ref-7"></a>[7] Longo, P. L., Mattos-Graner, R. O., & Mayer, M. P. A. (2001). Mutacinas: relação entre espectro de ação e detecção do gene mutA em amostras de Streptococcus mutans isoladas de indivíduos livres de cáries e carie ativos. *Scientific Publication*. https://www.semanticscholar.org/paper/8813fd1ca9dd582f8f0a02c62260dc4a4c353344

<a id="ref-9"></a>[9] Lynch, A. M., Howe, J., Hildebrand, D., Harvey, J. S., Burman, M., Harte, D. S. G., Chen, L., Kmett, C., Shi, W., Mchugh, C., Patel, K., Junnotula, V., Kenny, J., Howarth, R., & Wills, J. W. (2024). N-Nitrosodimethylamine investigations in Muta™Mouse define point-of-departure values and demonstrate less-than-additive somatic mutant frequency accumulations. *Mutagenesis*. https://www.semanticscholar.org/paper/f2f64a3b80f10af96df331d1dd5502d336251e80

<a id="ref-17"></a>[17] Al Mamun, A. A. M., Rahman, M. S., & Humayun, M. (1999). Escherichia coli cells bearing mutA, a mutant glyV tRNA gene, express a recA‐dependent error‐prone DNA replication activity. *Molecular Microbiology*. https://www.semanticscholar.org/paper/9b4d89fddf2b4c127ea04c58a718ea62076102af

<a id="ref-21"></a>[21] Vitellius, G., Trabado, S., Hoeffel, C., Bouligand, J., Bennet, A., Castinetti, F., Decoudier, B., Guiochon‐Mantel, A., Lombès, M., & Delemer, B. (2018). Significant prevalence of NR3C1 mutations in incidentally discovered bilateral adrenal hyperplasia: results of the French MUTA-GR Study. *European Journal of Endocrinology*. https://www.semanticscholar.org/paper/83025fffee9dee6ac5e544a9bc9b945d9337333a

<a id="ref-22"></a>[22] Murphy, H., & Humayun, M. (1997). Escherichia coli cells expressing a mutant glyV (glycine tRNA) gene have a UVM-constitutive phenotype: implications for mechanisms underlying the mutA or mutC mutator effect. *Journal of Bacteriology*. https://www.semanticscholar.org/paper/38a80df4c058178c9d9e1e967766a8e087493c83

<a id="ref-25"></a>[25] Dean, S., & Myhr, B. (1994). Measurement of gene mutation in vivo using Muta Mouse and positive selection for lacZ- phage. *Mutagenesis*. https://www.semanticscholar.org/paper/c6b1792bdd9463c3faad96eec746b6f1618efa4d

<a id="ref-31"></a>[31] Piccioli, P., Serra, M., Gismondi, V., Pedemonte, S., Loiacono, F., Lastraioli, S., Bertario, L., Angioletti, M., Notaro, R., & Nazionale Tumori. (2006). Multiplex Tetra-Primer Amplification Refractory Mutation System PCR to Detect 6 Common Germline Mutations of the MUTYH Gene Associated with Polyposis. *Scientific Publication*. https://www.semanticscholar.org/paper/b8913386a7f4d7f4938a30f584407fb6ee7fc8a3

<a id="ref-34"></a>[34] Brooks, T., Dean, S., & Kirkland, D. (1996). The detection of gene mutation in transgenic mice (Muta™ Mouse) following administration of known mutagens. *Scientific Publication*. https://www.semanticscholar.org/paper/1d1bdeb89fb68a7f706780b5b4c69502c7f15e43

<a id="ref-47"></a>[47] Wills, J., Johnson, G., Battaion, H. L., Slob, W., & White, P. (2017). Comparing BMD‐derived genotoxic potency estimations across variants of the transgenic rodent gene mutation assay. *Environmental and Molecular Mutagenesis*. https://www.semanticscholar.org/paper/df702e92692e65024f6b04154217d1a2a3874e27

<a id="ref-55"></a>[55] Sinitsyna, O., Volkov, P., Zorov, I., Rozhkova, A. M., Emshanov, O. V., Romanova, Y., Komarova, B. S., Novikova, N. S., Nifantiev, N., & Sinitsyn, A. (2025). Physico-chemical properties and substrate specificity of α-(1→3)-d-glucan degrading recombinant mutanase from Trichoderma harzianum expressed in Penicillium verruculosum. *Applied and Environmental Microbiology*. https://www.semanticscholar.org/paper/33c665e8304e16697d6494b776d4d186fe4054e9

<a id="ref-72"></a>[72] Wei, H., Scherer, M., Singh, A., Liese, R., & Fischer, R. (2001). Aspergillus nidulans alpha-1,3 glucanase (mutanase), mutA, is expressed during sexual development and mobilizes mutan. *Fungal Genetics and Biology*. https://www.semanticscholar.org/paper/fe1fc941e98d66d907eb4e1fa7afc9ce747c91fa

<a id="ref-77"></a>[77] Woodruff, W., Novak, J., & Caufield, P. (1998). Sequence analysis of mutA and mutM genes involved in the biosynthesis of the lantibiotic mutacin II in Streptococcus mutans. *Gene*. https://www.semanticscholar.org/paper/90933b385ba787222d7f8f2e339b8ec659d002e4

<a id="ref-81"></a>[81] Michaels, M., Cruz, C., & Miller, J. H. (1990). mutA and mutC: two mutator loci in Escherichia coli that stimulate transversions. *Proceedings of the National Academy of Sciences of the United States of America*. https://www.semanticscholar.org/paper/41a4ed4eba45bec8a6b1bffb9cd557124b9f697d

<a id="ref-85"></a>[85] Myhr, B. (1991). Validation studies with Muta™ mouse: A transgenic mouse model for detecting mutations in vivo. *Environmental and Molecular Mutagenesis*. https://www.semanticscholar.org/paper/515721e9f53f7700b0fd111f79fb277e5717abce

<a id="ref-86"></a>[86] Longo, P. L., Mattos-Graner, R., & Mayer, M. P. A. (2003). Determination of mutacin activity and detection of mutA genes in Streptococcus mutans genotypes from caries-free and caries-active children. *Oral Microbiology and Immunology*. https://www.semanticscholar.org/paper/440916c33e36028ccbcbd38e54da6d49628bc526

<a id="ref-92"></a>[92] Al Mamun, A. A. M., Gautam, S., & Humayun, M. (2006). Hypermutagenesis in mutA cells is mediated by mistranslational corruption of polymerase, and is accompanied by replication fork collapse. *Molecular Microbiology*. https://www.semanticscholar.org/paper/b3ae5637cbe369bccbc6f4afcbbe391ef8aa647f

<a id="ref-96"></a>[96] Eisenbeis, S., Nasoff, M., Stewart, A., Caruihers, M. H., Bracco, L., & Dodds, D. (2016). Altered Cro repressors from engineering of a synthetic cro gene. *Scientific Publication*. https://www.semanticscholar.org/paper/551112cfd4be3322f850e4ade7b9c2c9087b3bd4